Treatment of Mantle Cell Lymphoma

Initial Management Decisions

• The European Society for Medical Oncology recommends treatment of mantle cell lymphoma to be stratified by patient age, fitness level, and disease stage, with younger fit patients receiving intensive cytarabine-containing immunochemotherapy followed by autologous stem cell transplantation and rituximab maintenance, while elderly or unfit patients should receive bendamustine-rituximab (BR) or VR-CAP with rituximab maintenance 1, 2, 3
• Watch and wait is appropriate for indolent cases with low tumor burden under close observation, avoiding treatment toxicity in patients who may not require immediate intervention 4, 5

Advanced Stage Disease

• The American Society of Clinical Oncology recommends that younger fit patients receive intensive cytarabine-containing immunochemotherapy followed by ASCT consolidation and rituximab maintenance, achieving superior survival outcomes 1, 3
• The European Society for Medical Oncology recommends that elderly or unfit patients receive bendamustine-rituximab (BR) as the preferred first-line regimen, demonstrating superior progression-free survival compared to R-CHOP with better tolerability 1, 6

Relapsed/Refractory Disease

• The National Comprehensive Cancer Network recommends that relapsed mantle cell lymphoma be treated with targeted approaches including ibrutinib and lenalidomide, with ibrutinib showing the highest single-agent efficacy 2, 7
• Ibrutinib demonstrates the highest efficacy among single agents with an overall response rate of 68-72% and median PFS of 13.9-14.6 months 7

Special Considerations

• The European Society for Medical Oncology recommends that pleomorphic and blastoid variants require the same intensive approaches as classical MCL, and should not be undertreated based on histologic variant 3, 6
• Patients with TP53 mutation should be strongly considered for clinical trial enrollment, as conventional treatment yields poor outcomes 3